RBC

Innergex énergie renouvelable inc. est un chef de file canadien de l’industrie de l’énergie renouvelable. En activité depuis 1990, la Société développe, détient et gère des centrales hydroélectriques au fil de l’eau, des parcs éoliens et des parcs solaires photovoltaïques et elle exerce ses activités au Québec, en Ontario, en Colombie-Britannique, dans l'Idaho aux États-Unis et en France. Innergex Renewable Energy Inc. is a leading Canadian independent renewable power producer. Active since 1990, the Company develops, owns and operates run-of-river hydroelectric facilities, wind farms and solar photovoltaic farms and carries out its operations in Quebec, Ontario and British Columbia, Idaho, USA, and France.

Myelin uses AI to answer everyday questions about the mental health of caregivers, caregivers and affected people, with their first prototype focusing on those on the autism spectrum.

Composites Vci is a transportation environmental consulting company located in Saint-lin-laurentides.

Home Capital Group is a specialty finance company based in Canada, primarily engaged in residential and commercial mortgage lending. It also offers the securitization of insured mortgage products, consumer lending, and credit card services. The company serves a niche market by focusing on homeowners who may not meet the stringent lending criteria of traditional banks. Home Capital Group provides deposit services through brokers and financial planners, as well as via its direct-to-consumer brand, Oaken Financial. Additionally, it operates through its wholly owned subsidiary, Home Bank, and maintains offices across several provinces, including Ontario, Alberta, British Columbia, Nova Scotia, Quebec, and Manitoba.

The Creative Destruction Lab (CDL) is a seed-stage program designed to support the growth of scalable, science- and technology-driven ventures. Established in 2012 at the Rotman School of Management in Toronto, CDL employs an objectives-focused coaching process that connects startups with experienced entrepreneurs and leading scientists. The program concentrates on various sectors, including artificial intelligence, quantum computing, healthcare, and clean technology. With a presence in six cities, including Vancouver, Calgary, Toronto, Montreal, Halifax, and New York City, CDL aims to facilitate the commercialization of scientific advancements and technological innovations, fostering the development of promising startups in Canada and beyond.

CoPower Inc., founded in 2013 and headquartered in Canada, operates as an online platform focused on clean energy investing. It facilitates investments in energy efficiency and renewable energy generation projects, aiming to provide financial returns while also delivering measurable environmental benefits. Since late 2014, CoPower has successfully placed over $2.5 million in clean energy loans. The company is recognized as a Certified B Corporation, reflecting its commitment to social and environmental responsibility.

Opsens Inc. specializes in the development, manufacture, installation, and sale of fiber optic sensors, catering to various sectors including interventional cardiology, oil and gas, and industrial applications. The company operates through two primary segments: Medical and Industrial. The Medical segment focuses on physiological measurements such as fractional flow reserve (FFR) and provides miniature optical sensors for pressure and temperature measurement, essential for coronary artery stenosis diagnosis. It also licenses its optical sensor technology. The Industrial segment creates fiber optic sensing solutions applicable in diverse fields such as life sciences, energy, defense, and civil engineering. Notable products include OptoWire, an advanced optical pressure guidewire for coronary artery disease, and a range of fiber optic sensors for measuring temperature, pressure, strain, and displacement. Opsens distributes its products through a direct sales force and partnerships with distributors in the United States, Japan, Canada, and other international markets. Headquartered in Québec, Canada, Opsens is recognized for its high-accuracy sensors that are particularly beneficial in clinical environments.

Liminal BioSciences is a biopharmaceutical corporation supplying state-of-the-art technologies for bio-separations as well as therapeutic products. It specializes in discovering, developing, and commercializing novel small molecule compounds for respiratory, liver, and renal diseases. The company focuses specifically on developing solutions for rare and orphan diseases. Liminal BioSciences was founded in 1992 and is headquartered in Laval, Quebec.

Osisko Gold Royalties is an intermediate precious metal royalty company based in Montreal, Quebec. It specializes in acquiring and managing a diverse portfolio of over 130 royalties, streams, and precious metal offtakes, primarily focused on North America. The company's most significant asset is a 5% net smelter return royalty on the Canadian Malartic Mine, the largest gold mine in Canada. In addition to its royalty interests, Osisko maintains stakes in several publicly traded resource companies, including Barkerville Gold Mines and Osisko Mining. The company operates under two main segments: managing precious metal royalties and the exploration and development of mining projects. Osisko's income is predominantly generated from North America, with ongoing exploration efforts in various locations, including the Hammond Reef Project in Ontario and other ventures in Mexico.

Opsens Inc. specializes in the development, manufacture, installation, and sale of fiber optic sensors, catering to various sectors including interventional cardiology, oil and gas, and industrial applications. The company operates through two primary segments: Medical and Industrial. The Medical segment focuses on physiological measurements such as fractional flow reserve (FFR) and provides miniature optical sensors for pressure and temperature measurement, essential for coronary artery stenosis diagnosis. It also licenses its optical sensor technology. The Industrial segment creates fiber optic sensing solutions applicable in diverse fields such as life sciences, energy, defense, and civil engineering. Notable products include OptoWire, an advanced optical pressure guidewire for coronary artery disease, and a range of fiber optic sensors for measuring temperature, pressure, strain, and displacement. Opsens distributes its products through a direct sales force and partnerships with distributors in the United States, Japan, Canada, and other international markets. Headquartered in Québec, Canada, Opsens is recognized for its high-accuracy sensors that are particularly beneficial in clinical environments.

CoPower Inc., founded in 2013 and headquartered in Canada, operates as an online platform focused on clean energy investing. It facilitates investments in energy efficiency and renewable energy generation projects, aiming to provide financial returns while also delivering measurable environmental benefits. Since late 2014, CoPower has successfully placed over $2.5 million in clean energy loans. The company is recognized as a Certified B Corporation, reflecting its commitment to social and environmental responsibility.

Osisko Gold Royalties is an intermediate precious metal royalty company based in Montreal, Quebec. It specializes in acquiring and managing a diverse portfolio of over 130 royalties, streams, and precious metal offtakes, primarily focused on North America. The company's most significant asset is a 5% net smelter return royalty on the Canadian Malartic Mine, the largest gold mine in Canada. In addition to its royalty interests, Osisko maintains stakes in several publicly traded resource companies, including Barkerville Gold Mines and Osisko Mining. The company operates under two main segments: managing precious metal royalties and the exploration and development of mining projects. Osisko's income is predominantly generated from North America, with ongoing exploration efforts in various locations, including the Hammond Reef Project in Ontario and other ventures in Mexico.

Labrador Iron Mines is engaged in the mining of iron ore and in the exploration and development of direct shipping iron ore projects (the "Schefferville Projects") in the central part of the prolific Labrador Trough region, one of the major iron ore producing regions in the world, situated in the Menihek area in the Province of Newfoundland and Labrador and in the Province of Quebec, centered near the town of Schefferville, Quebec. The Schefferville Projects consist of the James Mine and adjacent Stage 1 deposits and Silver Yards processing facility, the Stage 2 Houston property, which includes the Malcolm 1 deposit, the Stage 3 Howse property, held in a joint venture with Tata Steel Minerals Canada Limited ("TSMC") and, subject to further exploration and development, other iron ore properties in the vicinity of Schefferville. LIM's Schefferville Projects are connected by a direct railway to the Port of Sept-Iles on the Atlantic Ocean and benefit from established infrastructure, including, the town, airport, roads, hydro power and rail service. LIM's Schefferville Projects comprise 20 different iron ore deposits, which were part of the original Iron Ore Company of Canada ("IOC") direct shipping operations conducted from 1954 to 1982 and formed part of the 250 million tonnes of historical reserves and resources previously identified by IOC. These historical resources estimates are based on work completed and estimates prepared by IOC prior to 1983 and were not prepared in accordance with NI 43-101. LIM's iron ore deposits which comprise the Schefferville Projects are divided into two separate portions, one within the Province of Newfoundland and Labrador and the other within the Province of Quebec. Since production commenced in June 2011, LIM has completed three operating seasons and has sold 23 shipments totalling 3.6 million dry tonnes (3.8 million wet tonnes) of iron ore into the Chinese spot market. LIM did not undertake any mining operations for the 2014 operating season due to a combination of the prevailing low price of iron ore, an assessment of the current economics of its deposits and a strategic shift in corporate focus towards establishing a lower cost operating framework, while concurrently negotiating the commercial terms of major contracts. LIM's current focus is seeking additional financing and completing a debt restructuring. The Company is also working on development of the Houston Mine, to be in a position to complete construction and begin mining operations from Houston when market conditions permit, subject to completion of financing and negotiation of major contracts.

VM6 provides enterprise-class virtualization to remote locations and SMB without the complexity or cost of traditional solutions. Designed for remote office and SMB budgets and capabilities, VM6 VMex harnesses the power of virtualization to provide server consolidation, management, shared storage and high availability without the need for costly consultants, professional services, training or specialized skill sets other than the MSCEs our customers already have on staff.

MethylGene Inc. (TSX:MYG) is a publicly-traded, clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics with a focus on cancer. The Company's product candidates include: MGCD265, an oral, multi-targeted kinase inhibitor targeting the Met, VEGF, Ron and Tie-2 receptor tyrosine kinases that is in multiple clinical trials for cancer; MGCD290, a fungal Hos2 inhibitor for use in combination with fluconazole for serious fungal infections which has completed Phase I clinical studies; and mocetinostat (MGCD0103), an oral, isoform-selective HDAC inhibitor for cancer which has been in multiple Phase II clinical trials and is currently in a Phase II trial in refractory or relapsed follicular lymphoma. Mocetinostat is licensed to Taiho Pharmaceutical Co. Ltd in certain Asian countries. A fourth compound discovered using MethylGene's HDAC platform, EVP-0334 - a potential cognition enhancing agent for neurodegenerative diseases has successfully completed Phase I trials sponsored by EnVivo Pharmaceuticals Inc. MethylGene also has a funded collaboration with Otsuka Pharmaceutical Co. Ltd. for applications in ocular diseases using the Company's proprietary kinase inhibitor chemistry.